The Technical Analyst
Harmony Biosciences [HRMY]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Harmony Biosciences Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.65% $29.22
America/New_York / 19 apr 2024 @ 12:40
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 658.79 mill |
| EPS: | 2.13 |
| P/E: | 13.72 |
| Earnings Date: | Apr 30, 2024 |
| SharesOutstanding: | 56.77 mill |
| Avg Daily Volume: | 0.364 mill |
| RATING 2024-04-19 |
|---|
| A+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Buy | |
| P/E: | Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 13.72 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 2.33x |
| Company: PE 13.72 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 27.81 - 30.61 ( +/- 4.80%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-29 | Kapadia Sandip | Buy | 15 000 | Common Stock |
| 2024-03-29 | Kapadia Sandip | Sell | 15 000 | Restricted Stock Units |
| 2024-03-29 | Kapadia Sandip | Sell | 8 013 | Common Stock |
| 2024-03-15 | Dierks Jeffrey | Buy | 11 979 | Common Stock |
| 2024-03-15 | Dierks Jeffrey | Sell | 9 644 | Stock Option |
| INSIDER POWER |
|---|
| 17.42 |
| Last 99 transactions |
| Buy: 1 264 876 | Sell: 2 130 732 |
Forecast:
14:19 - $29.22
Live Trading Signals (every 1 min)
Forecast
1: 12:49 - $29.20
Forecast 2: 13:39 - $29.24
Forecast 3: 14:19 - $29.22
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $29.22 (0.65% ) |
| Volume | 0.0805 mill |
| Avg. Vol. | 0.364 mill |
| % of Avg. Vol | 22.08 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For HRMY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $33.63 | N/A | Active |
|---|
HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Latest Press Releases
2024-04-16 08:05:00 - Press Release
Harmony Biosciences To Report First Quarter 2024 Financial Results On April 30, 2024
Plymouth meeting, pa. , april 16, 2024 /prnewswire/ -- harmony biosciences holdings, inc. (nasdaq: hrmy) today announced that it will report first quarter 2024 financial results on tuesday, april 30, 2024, before the open of the u.s. financial markets.
2024-04-11 08:05:00 - Press Release
Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize Tpm-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist
Plymouth meeting, pa. , april 11, 2024 /prnewswire/ -- harmony biosciences holdings, inc. (nasdaq: hrmy) today announced an exclusive licensing agreement with bioprojet to develop, manufacture and commercialize tpm-1116, a highly potent and selective oral orexin-2 receptor (ox2r) agonist that will be evaluated for the treatment of narcolepsy and other sleep/wake disorders.
2024-04-03 08:05:00 - Press Release
Harmony Biosciences Initiates Global Phase 3 Registrational Trial (tempo Study) Of Pitolisant In Patients With Prader-willi Syndrome
Plymouth meeting, pa. , april 3, 2024 /prnewswire/ -- harmony biosciences holdings, inc. ("harmony") (nasdaq: hrmy) has initiated its global phase 3 registrational trial, the tempo study, to evaluate the safety and efficacy of pitolisant as a treatment for excessive daytime sleepiness (eds) and behavioral symptoms in patients aged six years and older with prader-willi syndrome (pws).
2024-03-26 08:05:00 - Press Release
Harmony Biosciences To Participate In 23rd Annual Needham Virtual Healthcare Conference
Plymouth meeting, pa. , march 26, 2024 /prnewswire/ -- harmony biosciences holdings, inc. (nasdaq: hrmy), today announced that harmony's management team will participate in a fireside chat at the upcoming 23rd annual needham virtual healthcare conference on monday, april 8, 2024, at 9:30 a.m.
2024-02-28 08:05:00 - Press Release
Harmony Biosciences To Participate In Upcoming Investor Conferences
Plymouth meeting, pa. , feb. 28, 2024 /prnewswire/ -- harmony biosciences holdings, inc. (nasdaq: hrmy), today announced that harmony's management team will participate in the following upcoming investor conferences: leerink partners global biopharma conference 2024 location: miami fireside chat: monday, march 11, 2024, at 12:40 p.m.
Latest News
2024-04-16 08:05:00 - PRNewsWire
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024
PLYMOUTH MEETING, Pa. , April 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 financial results on Tuesday, April 30, 2024, before the open of the U.S. financial markets.
2024-02-28 08:05:00 - PRNewsWire
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
PLYMOUTH MEETING, Pa. , Feb. 28, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences: Leerink Partners Global Biopharma Conference 2024 Location: Miami Fireside Chat: Monday, March 11, 2024, at 12:40 p.m.
2024-02-23 12:41:03 - Zacks Investment Research
HRMY vs. TECH: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Techne (TECH). But which of these two stocks is more attractive to value investors?
2024-02-22 09:45:19 - Zacks Investment Research
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q4 Earnings and Revenue Estimates
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $1.01 per share a year ago.
2024-02-12 09:28:18 - InvestorPlace
The 3 Most Undervalued Small-Cap Stocks to Buy in February 2024
There are many types of companies in the financial markets, firstly from different sectors, and secondly, they can vary according to their capitalization size. Their capitalization can go by various factors, either the time they have been in the stock market, their attractiveness, or the great appetite of investors for the company, among many others.
2024-02-08 08:05:00 - PRNewsWire
HARMONY BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ON FEBRUARY 22, 2024
PLYMOUTH MEETING, Pa. , Feb. 8, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2023 financial results on Thursday, February 22, 2024, before the open of the U.S. financial markets.
2024-02-07 12:41:16 - Zacks Investment Research
HRMY or ILMN: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?
2024-02-07 12:36:48 - InvestorPlace
The 3 Most Undervalued Russell 2000 Stocks to Buy in February 2024
When it comes to undervalued Russell 2000 stocks, the narrative for targeting this specific space is the same as any other market-based motivation: buy low, sell high. It's just that with the Russell 2K index, we're dealing with smaller-capitalization enterprises.
2024-01-23 10:56:12 - Zacks Investment Research
Wall Street Analysts Believe Harmony Biosciences Holdings, Inc. (HRMY) Could Rally 28.77%: Here's is How to Trade
The mean of analysts' price targets for Harmony Biosciences Holdings, Inc. (HRMY) points to a 28.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-01-22 12:41:30 - Zacks Investment Research
HRMY vs. RGEN: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two stocks is more attractive to value investors?